First AD

Second AD

Mantle Cell Lymphoma

JAN-22-OSD1185 - /clinical/mantle-cell-lymphoma

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment.  This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Optimizing Bruton Kinase (BTK) Inhibitors in Relapsed/Refractory (R/R) Mantle Cell Lymphoma

Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

Overview of Mantle Cell Lymphoma

Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma

Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma

Future Directions in the Treatment of Mantle Cell Lymphoma